<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065609</url>
  </required_header>
  <id_info>
    <org_study_id>201307037</org_study_id>
    <secondary_id>R21CA182945</secondary_id>
    <nct_id>NCT02065609</nct_id>
  </id_info>
  <brief_title>89ZrTrastuzumab Breast Imaging With Positron Emission Tomography</brief_title>
  <official_title>Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with
      89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability after 89Zr-Trastuzumab Administration</measure>
    <time_frame>30 Days following 89Zr-Trastuzumab Administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>89Zr-Trastuzumab Human Dosimetry and Safety</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Lesion Detection and Safety</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HER2 Positive Lesion Detection and Safety</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-Trastuzumab Human Dosimetry and Safety</intervention_name>
    <description>PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2: Lesion Detection and Safety</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HER2 Positive Lesion Detection and Safety</intervention_name>
    <description>Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2: Lesion Detection and Safety</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients 18 years of age or older

          -  Cohort 1: Her2-positive (defined as 3+) or FISH HER2:CEP17 ratio &gt; 2 biopsy proven
             breast cancer

          -  Cohort 2: Her2-positive (defined as 3+) or FISH HER2:CEP17 ratio &gt; 2 OR HER2negative
             (0 or 1+, 2+ and FISH negative) biopsy-proven breast cancer

          -  Primary or recurrent/metastatic lesion size â‰¥ 1.5 cm as determined by imaging studies
             (ultrasonography, mammography, CT or MRI) or physical examination

          -  Able to give informed consent

          -  Not currently pregnant or nursing: Subject must be surgically sterile (has had a
             documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal
             (cessation of menses for more than 1 year), non-lactating, or of childbearing
             potential for whom a urine pregnancy test (with the test performed within the 24 hour
             period immediately prior to administration of 89Zr-trastuzumab) is negative

          -  Patients currently receiving trastuzumab therapy with or without other types of
             systemic therapy can participate if their disease progresses (development of new
             lesion(s) or worsening of known lesion(s) based on imaging modalities or physical
             examination.

        Exclusion Criteria:

          -  Patients with other invasive malignancies, with the exception of non- melanoma skin
             cancer, who had (or have) any evidence of the other cancer present within the last 5
             years

          -  Unable to tolerate 60 min of PET imaging per imaging session
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farrokh Dehdashti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Frye, CNMT, PET, CCRC</last_name>
    <phone>314-747-1604</phone>
    <email>fryej@mir.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Frye, MBA, CNMT, PET, NCT</last_name>
    <phone>314-362-7026</phone>
    <email>fryes@mir.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine @ Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Frye, CNMT, PET, CCRC</last_name>
      <phone>314-747-1604</phone>
      <email>fryej@mir.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Frye, MBA, CNMT, PET, NCT</last_name>
      <phone>314-362-7026</phone>
      <email>fryes@mir.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Farrokh Dehdashti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Farrokh Dehdashti</investigator_full_name>
    <investigator_title>Profesior of Radiology</investigator_title>
  </responsible_party>
  <keyword>Trastuzumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

